All HHS Contracts — May 02, 2026

$241,937,500 outlayed to date on the firm fixed price award since 2021-05-25 signals strong execution momentum in basic health R&D services.

Full and open competition win by a nonprofit limits investment appeal for equity portfolios despite $270M obligation and high outlays.

High pricing risk for GLOBAL HEALTH INVESTMENT CORPORATION under firm fixed price structure on $269.9M HHS/ASPR/BARDA health R&D contract.

Long-term HHS commitment to GLOBAL HEALTH INVESTMENT CORPORATION via BARDA Ventures OTA with potential extension from 2031-06-01 to 2041-06-01.

$269,952,453 firm fixed price award to GLOBAL HEALTH INVESTMENT CORPORATION via full and open competition, with $241.9M (90%) outlayed, evidences multi-decade commitment to basic health R&D (PSC AN41).

{"entity"=>"GLOBAL HEALTH INVESTMENT CORPORATION", "reason"=>"Track remaining ~$28M outlay on $269.9M HHS BARDA Ventures contract and long-term performance given high pricing risk.", "trigger"=>"Outlay updates, 2031-06-01 current end date, potential 2041-06-01 extension"}

{"entity"=>"Health R&D sector", "reason"=>"$270M HHS obligation signals policy priority for health preparedness R&D via BARDA Ventures OTA.", "trigger"=>"BARDA Ventures OTA performance milestones"}